These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36275363)

  • 1. STAG2 expression is associated with adverse survival outcomes and regulates cell phenotype in muscle-invasive bladder cancer.
    Athans S; Krishnan N; Ramakrishnan S; Cortes Gomez E; Lage-Vickers S; Rak M; Kazmierczak Z; Ohm J; Attwood K; Wang J; Woloszynska A
    Cancer Res Commun; 2022 Oct; 2(10):1129-1143. PubMed ID: 36275363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of STAG2 in bladder cancer.
    Aquila L; Ohm J; Woloszynska-Read A
    Pharmacol Res; 2018 May; 131():143-149. PubMed ID: 29501732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent truncating mutations of STAG2 in bladder cancer.
    Solomon DA; Kim JS; Bondaruk J; Shariat SF; Wang ZF; Elkahloun AG; Ozawa T; Gerard J; Zhuang D; Zhang S; Navai N; Siefker-Radtke A; Phillips JJ; Robinson BD; Rubin MA; Volkmer B; Hautmann R; Küfer R; Hogendoorn PC; Netto G; Theodorescu D; James CD; Czerniak B; Miettinen M; Waldman T
    Nat Genet; 2013 Dec; 45(12):1428-30. PubMed ID: 24121789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes.
    Taylor CF; Platt FM; Hurst CD; Thygesen HH; Knowles MA
    Hum Mol Genet; 2014 Apr; 23(8):1964-74. PubMed ID: 24270882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of STAG2 causes aneuploidy in normal human bladder cells.
    Li X; Zhang TW; Tang JL; Fa PP; Lu JX; Qi FM; Cai ZM; Liu CX; Sun XJ
    Genet Mol Res; 2015 Mar; 14(1):2638-46. PubMed ID: 25867412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stromal antigen 2 functions as a tumor suppressor in bladder cancer cells.
    Wang H; Zhong J; Wu C; Liu Y; Zhang J; Zou X; Chen Y; Su J; Yang G; Zhong Y; Tang A
    Oncol Rep; 2017 Aug; 38(2):917-925. PubMed ID: 28627627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of STAG2-Mutant Bladder Cancers by Immunohistochemistry.
    Park Y; Lelo A; Harris B; Berry DL; Chaldekas K; Kim JS; Waldman T
    Methods Mol Biol; 2023; 2684():145-151. PubMed ID: 37410232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intact Cohesion, Anaphase, and Chromosome Segregation in Human Cells Harboring Tumor-Derived Mutations in STAG2.
    Kim JS; He X; Orr B; Wutz G; Hill V; Peters JM; Compton DA; Waldman T
    PLoS Genet; 2016 Feb; 12(2):e1005865. PubMed ID: 26871722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy.
    Balbás-Martínez C; Sagrera A; Carrillo-de-Santa-Pau E; Earl J; Márquez M; Vazquez M; Lapi E; Castro-Giner F; Beltran S; Bayés M; Carrato A; Cigudosa JC; Domínguez O; Gut M; Herranz J; Juanpere N; Kogevinas M; Langa X; López-Knowles E; Lorente JA; Lloreta J; Pisano DG; Richart L; Rico D; Salgado RN; Tardón A; Chanock S; Heath S; Valencia A; Losada A; Gut I; Malats N; Real FX
    Nat Genet; 2013 Dec; 45(12):1464-9. PubMed ID: 24121791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle-Invasive Bladder Cancer.
    Lelo A; Prip F; Harris BT; Solomon D; Berry DL; Chaldekas K; Kumar A; Simko J; Jensen JB; Bhattacharyya P; Mannion C; Kim JS; Philips G; Dyrskjøt L; Waldman T
    Clin Cancer Res; 2018 Sep; 24(17):4145-4153. PubMed ID: 29954776
    [No Abstract]   [Full Text] [Related]  

  • 11. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
    Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent truncating mutations of STAG2 in bladder cancer.
    Black P
    Urology; 2014 Apr; 83(4):691-2. PubMed ID: 24486001
    [No Abstract]   [Full Text] [Related]  

  • 13. Complete loss of STAG2 expression is an indicator of good prognosis in patients with bladder cancer.
    Qiao Y; Zhu X; Li A; Yang S; Zhang J
    Tumour Biol; 2016 Aug; 37(8):10279-86. PubMed ID: 26838030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bladder cancer: STAG2 in the spotlight--have genomic studies identified a plausible biomarker?
    Razzak M
    Nat Rev Urol; 2013 Dec; 10(12):675. PubMed ID: 24189933
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative Analysis of Differentially Mutated Genes in Non-Muscle and Muscle-Invasive Bladder Cancer in the Chinese Population by Whole Exome Sequencing.
    Wang F; Dong X; Yang F; Xing N
    Front Genet; 2022; 13():831146. PubMed ID: 35419031
    [No Abstract]   [Full Text] [Related]  

  • 16. STAG2 loss-of-function affects short-range genomic contacts and modulates the basal-luminal transcriptional program of bladder cancer cells.
    Richart L; Lapi E; Pancaldi V; Cuenca-Ardura M; Pau EC; Madrid-Mencía M; Neyret-Kahn H; Radvanyi F; Rodríguez JA; Cuartero Y; Serra F; Le Dily F; Valencia A; Marti-Renom MA; Real FX
    Nucleic Acids Res; 2021 Nov; 49(19):11005-11021. PubMed ID: 34648034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De novo loss-of-function variants in STAG2 are associated with developmental delay, microcephaly, and congenital anomalies.
    Mullegama SV; Klein SD; Mulatinho MV; Senaratne TN; Singh K; ; Nguyen DC; Gallant NM; Strom SP; Ghahremani S; Rao NP; Martinez-Agosto JA
    Am J Med Genet A; 2017 May; 173(5):1319-1327. PubMed ID: 28296084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aneuploidy in neuroblastoma tumors is not associated with inactivating point mutations in the STAG2 gene.
    Djos A; Fransson S; Kogner P; Martinsson T
    BMC Med Genet; 2013 Oct; 14():102. PubMed ID: 24088605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STAG2 Protein Expression in Non-muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes.
    Gordon NS; Humayun-Zakaria N; Goel A; Abbotts B; Zeegers MP; Cheng KK; James ND; Arnold R; Bryan RT; Ward DG
    Eur Urol Open Sci; 2022 Apr; 38():88-95. PubMed ID: 35495284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational inactivation of STAG2 causes aneuploidy in human cancer.
    Solomon DA; Kim T; Diaz-Martinez LA; Fair J; Elkahloun AG; Harris BT; Toretsky JA; Rosenberg SA; Shukla N; Ladanyi M; Samuels Y; James CD; Yu H; Kim JS; Waldman T
    Science; 2011 Aug; 333(6045):1039-43. PubMed ID: 21852505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.